BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas ...

Becton, Dickinson and Company (BD) has announced a trial utilising the BD Libertas wearable injector for subcutaneous delivery of biologics. The decision to employ the injector in this first ...

BD has struck a $24 billion deal to buy C.R. Bard. The takeover will strengthen BD’s position in the markets for catheters, pumps and other items while also giving it a bigger presence in fast ...

BD maintains solid financial metrics with a gross profit margin of 46% and healthy cash flows, positioning the company well for its strategic initiatives in connected care technology.

The U.S. Centers for Disease Control and Prevention has issued a health advisory on a shortage of plastic Becton Dickinson and Co. Bactec blood culture media bottles.

LONDON-- (BUSINESS WIRE)--bd-capital, the pan-European, operator-led investment firm, is pleased to announce the final closing of its second fund, bd-capital Fund 2 (“Fund 2”), at €430 ...